Compounds > n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride
Page last updated: 2024-12-07

n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride: structure given in first source; a lipid regulator [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID131678
CHEMBL ID542103
SCHEMBL ID5973583
MeSH IDM0212874

Synonyms (38)

Synonym
nevanimibe hydrochloride [usan]
unii-tk694zfs57
133825-81-7
tk694zfs57 ,
pd 132301-2
n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride
n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hcl
pd132301-2
pd-132301-2
urea, n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)-, monohydrochloride
pd 132301-02
atr-101
atr-101 hydrochloride
pd132301-02
CHEMBL542103 ,
pd-132301 hydrochloride
nevanimibe hydrochloride
pd-132301-02
urea, n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)-, hydrochloride (1:1)
n-(2,6-bis(propan-2-yl)phenyl)-n'-((1-(4-(dimethylamino)phenyl) cyclopentyl)methyl)urea hydrochloride
SCHEMBL5973583
DTXSID10158389
133825-81-7 (hcl)
AKOS032954251
atr-101 hcl
nevanimibe hydrochloride (usan)
D11311
1-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]-3-[2,6-di(propan-2-yl)phenyl]urea;hydrochloride
1-(2,6-diisopropylphenyl)-3-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride
HY-100399A
CS-0018786
Q27289998
MS-28369
urea, n-[2,6-bis(1-methylethyl)phenyl]-n'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]-, hydrochloride (1:1)
atr101 hydrochloride
atr101 hydrochloridepd-132301 hydrochloride
urea, n-[2,6-bis(1-methylethyl)phenyl]-n inverted exclamation marka-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]-, hydrochloride (1:1)
1[[1[4(dimethylamino)phenyl]cyclopentyl]methyl]3[2,6di(propan2yl)phenyl]urea hydrochloride
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)0.05200.00020.552110.0000AID31069
Acyl-CoA:cholesterol acyltransferase Oryctolagus cuniculus (rabbit)IC50 (µMol)0.05200.00600.98467.6000AID31069
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID172583Compound was evaluated in experiment 1 for change in non High density lipoprotein at the doses at 0.3 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID171573Compound was evaluated in experiment 1 for Change in High density lipoproteins at 10 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID174757Percent change in total cholesterol in peanut oil (5.5%)-, cholic acid (0.3%)-, Cholesterol (1.5%)-fed rats after a single dose.1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID171583Compound was evaluated in experiment 1 for Change in total cholesterol at 0.3 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID179920Compound was evaluated in experiment 1 for High density lipoproteins at 0.3 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID171571Compound was evaluated in experiment 1 for Change in High density lipoproteins at 0.3 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID171574Compound was evaluated in experiment 1 for Change in High density lipoproteins at 3.0 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID189410Compound was evaluated in experiment 2 for non High density lipoproteins at 30 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID179922Compound was evaluated in experiment 1 for High density lipoproteins at 10 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID172585Compound was evaluated in experiment 1 for change in non High density lipoprotein at the doses at 3.0 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID21340Solubility at, pH 7.41994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID189406Compound was evaluated in experiment 1 for non High density lipoproteins at 3.0(mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID171725Compound was evaluated in experiment 2 for Change in total cholesterol at 30 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID189952Compound was evaluated in experiment 2 for Total cholesterol at 30 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID171585Compound was evaluated in experiment 1 for Change in total cholesterol at 10 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID189404Compound was evaluated in experiment 1 for non High density lipoproteins at 1.0 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID21339Solubility at, pH 4.01994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID171586Compound was evaluated in experiment 1 for Change in total cholesterol at 3.0 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID179921Compound was evaluated in experiment 1 for High density lipoproteins at 1.0 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID172590Compound was evaluated in experiment 2 for change in non High density lipoprotein at the doses at 30 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID189403Compound was evaluated in experiment 1 for non High density lipoproteins at 0.3 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID172584Compound was evaluated in experiment 1 for change in non High density lipoprotein at the doses at 10 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID189947Compound was evaluated in experiment 1 for Total cholesterol at 10 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID171584Compound was evaluated in experiment 1 for Change in total cholesterol at 1.0 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID189946Compound was evaluated in experiment 1 for Total cholesterol at 1.0 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID172586Compound was evaluated in experiment 1 for change in non High density lipoprotein at the doses at 1.0 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID189405Compound was evaluated in experiment 1 for non High density lipoproteins at 10 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID171572Compound was evaluated in experiment 1 for Change in High density lipoproteins at 1.0 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID179923Compound was evaluated in experiment 1 for High density lipoproteins at 3.0 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID189945Compound was evaluated in experiment 1 for Total cholesterol at 0.3 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID189948Compound was evaluated in experiment 1 for Total cholesterol at 3.0 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID21338Solubility at, 0.1 N HCl1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID171578Compound was evaluated in experiment 2 for Change in High density lipoproteins at 30 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID31069Tested for in vitro inhibition against Acyl coenzyme A:cholesterol acyltransferase of intestinal microsomes in cholesterol-fed rabbits1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
AID180063Compound was evaluated in experiment 2 for High density lipoproteins at 30 (mg/kg) dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (61.54)18.2507
2000's0 (0.00)29.6817
2010's5 (38.46)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.61 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
metyrapone
Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.. metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.		1.9810aromatic ketoneantimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
adenosine diphosphate
Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.		2.3920adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
adenosine monophosphate
Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.		1.9810adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
pd 128042
PD 128042: structure given in first source		1.9810anilide
cl 277082
CL 277082: structure given in first source		1.9810
n-(2,6-bis(isopropyl)phenyl)-n'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea
nevanimibe: an inhibitor for the treatment of congenital adrenal hyperplasia		1.9810
D-fructopyranose
[no description available]		1.9810cyclic hemiketal;
D-fructose;
fructopyranose		sweetening agent
leukotriene b4
Leukotriene B4: The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene B4 : A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway.		1.9810dihydroxy monocarboxylic acid;
hydroxy polyunsaturated fatty acid;
leukotriene;
long-chain fatty acid		human metabolite;
mouse metabolite;
plant metabolite;
vasoconstrictor agent
ConditionIndicatedRelationship StrengthStudiesTrials
Adrenal Gland Diseases
Pathological processes of the ADRENAL GLANDS.		01.9810
Adrenocortical Carcinoma
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.		02.8330
Cushing's Syndrome
[description not available]		02.1710
Canine Diseases
[description not available]		02.1710
Cushing Syndrome
A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.		14.1710
Adrenal Cortex Cancer
[description not available]		02.5320
Adrenal Cortex Neoplasms
Tumors or cancers of the ADRENAL CORTEX.		14.5320
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9810
Anorexia
The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.		01.9810
Atrophy
Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.		01.9810
Adrenal Cortex Diseases
Pathological processes of the ADRENAL CORTEX.		01.9810
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		01.9810